Brian Szymczak - Jun 14, 2022 Form 3 Insider Report for Heart Test Laboratories, Inc. (HSCS)

Role
Director
Signature
/s/ Mark Hilz, Attorney-In-Fact
Stock symbol
HSCS
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
3
Date filed
7/6/2022, 01:41 PM
Next filing
Mar 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HSCS Common Stock 6.06K Jun 14, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 1.89K $3.47 Direct F1
holding HSCS Series C Convertible Preferred Stock Jun 14, 2022 Common Stock 1.52K $6.59 Direct F2
holding HSCS Warrants Jun 14, 2022 Common Stock 30 $2.89 Direct
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 1.89K $3.47 Direct F3
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 3.03K $1.29 Direct F4
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 1.89K $15.18 Direct F5
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 2.65K $15.18 Direct F6
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 5.3K $15.18 Direct F7
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 5.3K $12.21 Direct F8
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 3.03K $12.21 Direct F9
holding HSCS Director Stock Option (Right to Buy) Jun 14, 2022 Common Stock 3.03K $9.90 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The entire option has become fully-vested and may be exercised at any time at the Holder's election.
F2 The Convertible Preferred Stock may be converted at any time, at the Holder's election and there is no expiration. The conversion ratio is 3.7954 shares of Common Stock for each share of Series C Preferred Stock.
F3 The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
F4 The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
F5 The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
F6 The entire option has become fully-vested and may be exercised at any time at the Holder's election.
F7 The entire option has become fully-vested and may be exercised at any time at the Holder's election.
F8 The entire option has become fully-vested and may be exercised at any time at the Holder's election.
F9 The entire option has become fully-vested and may be exercised at any time at the Holder's election.
F10 The entire option has become fully-vested and may be exercised at any time at the Holder's election.